Abstract Non-adherence to insulin is common and associated with suboptimal health. We adapted the Morisky Medication Adherence Scale to specify insulin adherence (MIAS) and compared it to the Adherence to Refills and Medication Scale for Diabetes (ARMS-D) and the Summary of Diabetes Self-Care Activities medications subscale (SDSCA-MS) and an insulin-specific (SDSCA-IS) version. A sample of 144 insulin-treated adults (58 % African American/Black, 34 % Caucasian/White, 8 % Other/ Mixed race; 6.9 % Hispanic) completed these measures along with a HbA 1C test. The internal consistency and factor structure of the MIAS were adequate; 59 % of participants forgot to take insulin and 46 % reported non-adherence. The MIAS was associated with the ARMS-D, SDSCA-MS, and SDSCA-IS (p \ 0.001), and higher MIAS scores were marginally associated with better selfrated health (p = 0.057), but significantly associated with fewer emergency room visits (p = 0.001), and better HbA 1C (p = 0.001). The MIAS is a valid and reliable insulin adherence assessment tool for practice and research applications.
Introduction
Adults with type 2 diabetes (T2DM) are often prescribed oral glucose-lowering agents and/or insulin to achieve glycemic control, thereby preventing macrovascular and microvascular complications. Medication adherence facilitates these and other benefits, whereas medication nonadherence is associated with a cascade of unfavorable health outcomes, including suboptimal glycemic control (Feldman et al., 2014; Piette et al., 2004) , emergency room visits (Balkrishnan et al., 2003) , hospitalizations (Ho et al., 2006) , higher healthcare costs (Balkrishnan et al., 2003) , and pre-mature mortality (Ho et al., 2006) . The scope of the non-adherence problem depends on the population being studied (Peyrot et al., 2012a, b) , reasons for nonadherence, and how adherence is measured (i.e., self-report, pharmacy claims) (Gonzalez & Schneider, 2011) .
Currently, studies report adherence rates as low as 67 % for oral glucose-lowering agents (Cramer, 2004) and 43 % for insulin (Davies et al., 2013) . Certain populations have higher rates of non-adherence to diabetes treatment, including racial/ethnic minorities (Osborn et al., 2011a) , populations with low socioeconomic status (SES; defined as having a limited income, education, or lack of health insurance), and/or persons with more social stressors , limited health literacy (Osborn et al., 2011a) , and depression (Gonzalez et al., 2007; Osborn et al., 2011b) . Factors associated with non-adherence to insulin, specifically, include older age (Egede et al., 2011) , being female (Egede et al., 2011; Peyrot et al., 2010) , being a racial/ethnic minority (Cramer & Pugh, 2005) , having low SES and a T2DM diagnosis (versus type 1 diabetes) (Peyrot et al., 2010) , among other factors (Davies et al., 2013) .
The reasons for non-adherence to insulin also differ from adherence to oral glucose-lowering agents. Persons with T2DM who are non-adherent report omitting insulin doses because of fear and embarrassment with administration in public and the inflexibility and demands of the regimen (e.g., persons on adjustable insulin must adjust their insulin dose based on carbohydrate intake, physical activity and blood glucose levels) (Peyrot et al., 2012b) , the pain associated with injections (Rubin et al., 2009) , and fear of hypoglycemia and weight gain (Ross et al., 2011) . Insulin-treated patients also report more emotional distress than patients on oral medications (Baek et al., 2014) , and such distress is associated with both non-adherence and suboptimal glycemic control (Gonzalez et al., 2015) .
Globally, regardless of diabetes type, people treated with insulin struggle with regimen adherence and persistence. A 2012 international survey of insulin-treated persons with diabetes (88 % T2DM) found one in three omitted insulin or were non-adherent in the past month, with 3.3 average nonadherent days during that time (Peyrot et al., 2012b) . Some report 41-57 % of insulin-treated persons are non-adherent (Lerman et al., 2009; Peyrot et al., 2010) , with an estimated 20 % omitting insulin routinely (Peyrot et al., 2010) . These studies highlight the magnitude of insulin non-adherence among adults with T2DM, but rely on self-report measures of unknown reliability and validity created for the study.
All measures of medication adherence have strengths and limitations. Self-reported adherence is subject to social desirability bias, but strongly correlated with more objective measures (e.g., pharmacy claims data, medication event monitoring systems), which cannot assess the timing and accurate dosing of medications. While both subjective and objective measures predict clinical outcomes, self-report is more feasible for research purposes and clinical administration, especially for adjustable-dose regimens (Gonzalez & Schneider, 2011) . Current self-report measures of medication adherence in diabetes include the Adherence to Refills and Medications Scale for Diabetes (ARMS-D) (Mayberry et al., 2013) , the Summary of Diabetes Self-Care Activities Medication Subscale (SDSCA-MS) (Toobert et al., 2000) , and the Morisky Medication Adherence Scale (MMAS) (AlQazaz et al., 2010; Chung et al., 2015; DiBonaventura et al., 2014; Wong et al., 2014) . A major drawback of these measures is having respondents consider their entire glucoselowering regimen (orals and insulin) when responding to items rather than distinguishing between adherence to orals versus adherence to insulin.
To our knowledge, there is no gold standard self-report measure of insulin adherence, so we adapted the MMAS to specify insulin adherence (MIAS), examined its psychometric properties, and compared it to the ARMS-D and SDSCA, which are both correlated with objective adherence measures Kripalani et al., 2009 ) and glycemic control (Houle et al., 2015; Mayberry et al., 2013) . We also explored relationships between the MIAS and glycemic control, emergency room visits, and self-rated health, and tested if it explains unique variance in these outcomes above and beyond the ARMS-D and SDSCA.
Methods

Sample and Recruitment
From July 2010 through November 2012, we recruited 314 English-or Spanish-speaking adults (C18 years) prescribed medications for T2DM (i.e., insulin, insulin and oral agents, or oral agents only) at a Federally Qualified Health Center (FQHC) in Nashville, TN. Trained research assistants (RAs) worked with clinic personnel to identify eligible participants with a scheduled appointment (Mayberry et al., 2013; . For this paper, we have restricted the sample to only those participants prescribed insulin alone or in combination with oral agents (i.e., 144 participants).
Data and Procedure
Data collection and study procedures have been previously described (Mayberry et al., 2013; Mayberry and Osborn, 2014) , and approved by the Vanderbilt University Institutional Review Board. Informed consent and data collection occurred before or after participants' scheduled clinic appointment. Given high rates of limited literacy skills in FQHC patient populations, RAs read self-report items and response options aloud to all participants. To reduce social desirability bias and maximize accurate reporting, RAs told participants their self-report data would not be shared with healthcare providers and, consistent with instructions, normalized non-adherence prior to the administration of each adherence measure. Finally, RAs obtained medical record information, and compensated participants $20. A clinic nurse administered a point-of-care glycated hemoglobin A 1C (HbA 1C ) test to assess glycemic control.
Measures
Demographic and diabetes characteristics
We asked participants their date of birth and age, reconciling discrepancies with what was recorded in the medical record, as well as their gender, race, ethnicity, income, education, insurance status, and duration of diabetes. RAs collected body mass index (BMI) and the type of prescribed medications from the medical record.
Morisky Insulin Adherence Scale (MIAS)
With permission from Morisky (Morisky, personal communication) , we adapted the eight-item Morisky Medication Adherence Scale (MMAS; Morisky et al., 2008) to assess insulin adherence by replacing condition-specific language like ''blood pressure medicine'' with ''insulin,'' but retaining each item's meaning and scoring. Consistent with the MMAS (Morisky et al., 2008) , the MIAS includes seven yes/no questions and one question on a 5-point Likert scale. Respondents answering ''no'' to all questions, but ''yes'' to item 5 (reverse coded) and ''never/rarely'' to item 8 obtain the maximum 8 points and are classified as having perfect adherence. Respondents answering differently obtain a lower score, indicating less than perfect adherence (\ 8).
Adherence to Refills and Medications Scale for Diabetes (ARMS-D)
The 11-item ARMS-D asks respondents to think about all the diabetes medications they are taking (i.e., oral agents, insulin, or insulin plus oral agents) when responding to items assessing problems with filling and taking diabetes medications, including insulin (Mayberry et al., 2013) . We elected to administer the ARMS-D 'as is' rather than adapt it for insulin only to see if the MIAS does better than currently used measures that take insulin into account. Furthermore, while the ARMS-D is not an insulin-specific adherence measure, per se, insulin-treated participants completed the ARMS-D and their responses account for their problems taking insulin. We reversed the ARMS-D scores to be consistent with the direction of MIAS scores, so higher ARMS-D scores indicate better adherence.
Summary of Diabetes Self-Care Activities Medications Subscale (SDSCA-MS)
The two-item SDSCA-MS is one of the most widely used self-report measures of medication adherence in diabetes (Mayberry et al., 2013; Toobert et al., 2000) . Respondents are typically asked to think about all of their diabetes medications when answering two questions, but because adherence may be medication-specific, we administered both items separately for each diabetes medication in the regimen. RAs asked insulin-treated participants to list each insulin and oral diabetes medication in their regimen, separately, and then RAs asked (1) ''On how many of the last 7 days did you take this medication?'' and (2) ''On how many of the last 7 days did you take the correct number of (pills/injections) for this medication?'' Response options range from 0 to 7. We averaged these items as recommended (Toobert et al., 2000) , and then calculated the average of the averages (i.e., across insulin[s] and orals for those on both) to generate the typically calculated diabetes medication adherence score, with higher scores indicating better adherence (Mayberry et al., 2013) . We also calculated a separate score, representing participants' adherence to only their insulin(s), which we are calling the SDSCA-IS, with higher scores indicating better insulin adherence.
Self-rated health
RAs asked on a 5-point response scale, ranging from 1 = ''poor'' to 5 = ''excellent,'' ''In general, your overall health is?''
Emergency room (ER) visits
RAs asked, ''How many times have you been to the emergency room in the past year?' ' The response was open-ended.
Glycemic control (HbA 1C )
A nurse administered a point-of-care HbA 1C (%) test (Kennedy & Herman, 2005) . The HbA 1C test measures one's average blood glucose control over the past two to three months, and is the gold standard for assessing glycemic control. MMAS-assessed medication adherence is highly sensitive, with 88.9 % of non-adherent patients also having suboptimal glycemic control (Chung et al., 2015) .
Analyses
We used SPSS 21 for all analyses, and restricted our analyses to include only those participants prescribed insulin or insulin plus oral glucose-lowering agents (N = 144). Cronbach's a and item-total correlations assessed the MIAS' internal consistency reliability. Itemrest correlations C0.30 indicate items are conceptually similar to other items, and a Cronbach's a C 0.70 indicates good internal consistency reliability (DeVellis, 1991; Nunnally et al., 1994) . We performed a principal components factor analysis with a forced one-factor solution to test comparability with the MMAS (Morisky et al., 2008) . Items with loadings C0.40 share substantial variance with other items (Loehlin, 2012) . To examine convergent validity, Spearman's rho correlations tested the MIAS' association with overall diabetes medication adherence according to the ARMS-D and the SDSCA-MS, and insulin-specific adherence according to the SDSCA-IS.
Data were missing on three variables included in multivariable models; one participant did not know duration of diagnosed diabetes, three participants had missing BMI in the medical record, and 10 participants (6.9 %) did not report income. Casewise deletion biases estimates (Ware et al., 2012) and requires more assumptions about the missing data than multiple imputation, so we used multiple imputation with chained equations (Raghunathan et al., 2001; van Buuren et al., 1999) to impute 10 datasets (Graham et al., 2007 ) following Graham's guidelines (Graham, 2009; Graham & Schafer, 1999) .
To explore criterion validity, we related the MIAS to self-rated health, ER visits in the past year, and glycemic control. Linear regression models assessed the unadjusted and adjusted relationships between the MIAS and each outcome variable. Adjusted models included a priori covariates entered at the same time, including participants' age, gender, race, income, education, insurance status, duration of diabetes diagnosis, and BMI. Linear models assessed both the independent relationship between the MIAS and the outcome variable and the proportion of variance the MIAS explained in the outcome.
We also conducted three hierarchical linear regression models to test the unique contribution of the MIAS in predicting HbA 1C above and beyond each existing medication adherence measure. One model asks, ''Does the MIAS explain unique variance in HbA 1C compared to the ARMS-D (i.e., the medication adherence measure endorsed by the National Diabetes Education Program) before and after adjusting for age, gender, race, income, education, insurance status, duration of diabetes diagnosis, and BMI?'' Another model asks, ''Does the MIAS explain unique variance in HbA 1C compared to the SDSCA-MS (i.e., the most widely used medication adherence measure in diabetes) before and after adjusting for a priori covariates?'' The final model asks, ''Does the MIAS explain unique variance in HbA 1C compared to the SDSCA-IS (i.e., asking respondents to think of insulin only when responding to SDSCA items) before and after adjusting for covariates?'' Support for unique variance suggests the MIAS is assessing something above and beyond what is captured by existing measures of diabetes medication adherence.
Results
Sample characteristics for the 144 participants prescribed insulin are presented in Table 1 . These participants were on average 50.7 (SD = 11.9) years old; 38.9 % male; 58.3 % African American/Black; 31.9 % had less than a high school diploma or equivalent; 73.6 % had annual incomes less than $15 K; and 47.2 % were uninsured. The average participant had been diagnosed with diabetes for 10.0 (SD = 7.6) years, and presented with an HbA 1C of 9.0 % (SD = 2.1 %). The mean score for the MIAS was 5.35 (SD = 1.92). The MIAS item-total correlations were C0.30 for each item. Internal consistency reliability was a = 0.69, and did not improve with item deletion. The MIAS produced acceptable item loadings ranging from 0.48 to 0.68 that loaded onto a single factor (Table 2) . Better insulin adherence on the MIAS was associated with better diabetes medication adherence on the ARMS-D total (q = 0.66, p \ 0.001), ARMS-D refill adherence subscale (q = 0.35, p \ 0.001), ARMS-D medication taking subscale (q = 0.70, p \ 0.001), and the SDSCA-MS (q = 0.51, p \ 0.001). Insulin adherence on the MIAS was associated with insulin adherence on the SDSCA-IS (q = 0.48, p \ 0.001).
The proportion of participants reporting perfect adherence (i.e., the highest level of adherence measured by a scale) was 12.5 % on the MIAS, as compared to 0 % on the ARMS-D total, 54.2 % on the SDSCA-MS, and 58.3 % on the SDSCA-IS. Of participants reporting perfect adherence on the SDSCA-MS and SDSCA-IS, 82.1 % and 83.3 % reported less than perfect adherence on the MIAS, respectively. Of participants reporting perfect adherence on the MIAS (n = 18), 22 % reported less than 7 days adherence on the SDSCA-MS and the SDSCA-IS.
The MIAS was not significantly related to participants' age, gender, race, years of education, income, health insurance status, duration of diagnosed diabetes, or BMI, but was significantly associated with favorable health ratings, fewer ER visits in the past year, and lower HbA 1C (Table 3 ). In adjusted regression models, the MIAS was marginally associated with favorable health ratings, but remained significantly associated with fewer ER visits in the past year and lower HbA 1C (Table 3) . The MIAS explained a marginally significant amount of unique variance in self-rated health, but explained a significant and substantial amount of unique variance in ER visits and HbA 1C . The MIAS explained 11 % of unique variance in ER visits, representing a 69.5 % increase over the amount of variance explained by the covariates alone. While the MIAS explained 6.6 % of unique variance in HbA 1C , representing a 41.3 % increase in variance explained by the covariates, participants with controlled HbA 1C (\7 %, n = 22) were only marginally more adherent on the MIAS (M = 6.0 ± SD = 1.51) compared to participants with uncontrolled HbA 1C (C7 %, n = 122; M = 5.23 ± SD = 1.96), p = 0.09.
Three hierarchical linear regression models tested the unique contribution of the MIAS in predicting HbA 1C , independent of the ARMS-D, SDSCA-MS, and SDSCA-IS, and prior to and after adjusting for age, gender, race, income, education, insurance status, duration of diagnosed diabetes, and BMI. Table 4 presents the three-step models in which HbA 1C was regressed on one of the three validated measures of diabetes medication adherence (in Step 1), the MIAS (in Step 2), and covariates (in Step 3). In the first model, the ARMS-D was significantly associated with lower HbA 1C in Step 1 (b = -0.30, p \ 0.001), but this effect was reduced (b = -0.21, p = 0.049) with the MIAS. In Step 2, the MIAS was not associated with lower HbA 1C (b = -0.13, p = 0.225), but was marginally associated with lower HbA 1C in
Step 3 (b = -0.20, p = 0.057). In the second model, the SDSCA-MS was marginally associated with lower HbA 1C in Step 1 (b = -0.16, p = 0.05), but was not associated with HbA 1C in Steps 2 and 3, whereas the MIAS was significantly associated with lower HbA 1C in Steps 2 (b = -0.25, p = 0.006) and 3 (b = -0.22, p = 0.013). Finally, in the third model, the SDSCA-IS was marginally associated with 
Discussion
Studies assessing insulin adherence often rely on singleitem self-reports with unknown reliability and validity, use arbitrary cut-offs for non-adherence, or combine adherence to insulin and oral medications in a single assessment. To establish a self-report measure of insulin adherence, we adapted a widely used measure of medication adherence in clinical settings, the MMAS (Morisky et al., 2008) , to be insulin-specific (i.e., the MIAS), administered it to a sample of high risk patients, and assessed its psychometric properties. We found the MIAS to be a reliable and valid measure of insulin adherence, and that nearly half (45.8 %) of our sample reported episodes of insulin non-adherence during the previous two weeks and 21 % were non-adherent on the previous day. Chronbach's alpha assesses the degree to which items measure the same general construct. The MMAS has produced an acceptable [0.80 alpha (Morisky et al., 2008) , whereas the MIAS produced an adequate alpha of 0.69. This might be due to patients on short-acting adjustable insulin versus long acting insulin responding differently to items 2, 3, and 5 on the MIAS. These items ask about not taking all of your insulin or cutting back insulin, which might indicate adherence for patients on adjustable insulin, but non-adherence for patients on longacting insulin. Future studies should examine item performance by insulin type to account for this possibility.
Convergent validity was supported by significant correlations between the MIAS and the ARMS-D, a general diabetes medication adherence scale, and the SDSCA-MS, which estimates taking diabetes medications and correct dosing of these medications in the past 7 days. Discriminant validity was partially supported, as the MIAS was more closely related to the ARMS-D's medication taking subscale than the refill adherence subscale, but it was equally related to the number of days of taking diabetes medications and doses for both the overall SDSCA medications subscale and an insulin-specific version.
Criterion validity was strongly supported. The MIAS was significantly related to favorable health ratings, fewer ER visits in the past year, and better glycemic control. The MIAS accounted for 70 % more variance in ER visits and over 40 % more variance in HbA 1C than could be accounted for by demographic and clinical covariates alone. Moreover, the MIAS accounted for additional variance in HbA 1C (of marginal significance) over and above what could be predicted by the ARMS-D that assesses overall diabetes medication adherence. The MIAS also accounted for significantly more variance in HbA 1C than asking about days having taken diabetes medications and doses in general, or days having taken insulin and insulin doses, specifically, over the past 7 days (SDSCA-MS and SDSCA-IS). Although the magnitude of the relationship between insulin adherence and HbA 1C was statistically significant, analyses indicated approximately 7 % shared variance. This is somewhat better than what is typical for studies assessing the relationship between adherence and glycemic control in T2DM, even when adherence is objectively measured. Medication adherence based on prescription refill data accounted for 4 % of the variance in concurrently measured HbA 1C and only 1.7 % in HbA 1C change over time in a prior study of 810 low-income African American/Black and Caucasian/White adults with diabetes (Schectman et al., 2002) . An Israeli populationbased study of 228,846 adults with diabetes indicated approximately 4.5 % shared variance between the medication possession ratio and glycemic control (Feldman et al., 2014) . Another study found shared variance between various self-report measures of medication adherence and glycemic control ranging from 3 to 8 % (Kripalani et al., 2009) . Our results suggest the MIAS shares some overlap with existing measures of medication adherence, but accounts for additional information relevant to understanding the risk of suboptimal outcomes among racially/ ethnically diverse, low SES insulin users with T2DM. Prior studies of insulin adherence have used self-report scales of unknown psychometric properties, often using a single item that asks patients to give an overall estimate of the frequency of intentionally taking less insulin than prescribed or unintentionally missing prescribed doses (Peyrot et al., 2010 (Peyrot et al., , 2012a . Unlike the SDSCA (Toobert et al., 2000) , but similar to the ARMS-D, the MIAS has the advantage of using multiple items to identify common reasons for non-adherence that can be addressed in clinical practice or in interventions to improve adherence. Forgetting to take insulin doses was the most frequently endorsed MIAS item (59 %), but nearly half (47.9 %) felt hassled by insulin, whereas one in five reported intentional non-adherence to avoid negative consequences of insulin (23.6 %) or because they felt diabetes was under control (21.5 %). These rates differ from the 2012 U.S. National Health and Wellness Survey (NHWS) reporting overall medication adherence for adults with T2DM on insulin (DiBonaventura et al., 2014) . Among 1198 respondents taking insulin glargine or detemir, 20 % reported forgetting to take their medication, 29 % felt hassled by their medication regimen, and less than 7 % reported each type of intentional nonadherence (DiBonaventura et al., 2014) . The NHWS did not assess insulin-specific adherence, so our higher rates of insulin non-adherence problems might reflect differences in adherence to insulin versus oral medications, differences in samples, or a combination of both. Our sample was younger, included more African American/Black participants with lower SES who had worse glycemic control in comparison. The relatively high rates of insulin non-adherence and perceived hassles related to insulin in our sample of low SES patients underscore the importance of assessing insulin-specific adherence in this population. Step 1 ARMS-D
Step 2 MIAS
Step 3 a priori covariates
Step 1 SDSCA-MS
Step 1 SDSCA-IS
Step 1 There are study limitations. Our cross-sectional design precluded testing if the MIAS, ARMS-D, SDSCA-MS and SDCSA-IS predict future health ratings, ER visits, and glycemic control. We were unable to assess test-retest reliability, compare these measures' concordance with objective adherence measures, test the MIAS' divergent validity with unrelated measures, explore between group differences in the MIAS by duration and type of insulin therapy, or assess social-desirability bias. Furthermore, results may differ from those presented here if measurement administration is done by a non-RA (e.g., clinician) or does not include a statement normalizing non-adherence, or if the SDSCA-MS and SDSCA-IS are not administered for each medication or insulin, separately. While we achieved the absolute minimum number of cases per predictor in regression models (VanVoorhis and Morgan 2007), our sample size was small, limiting statistical power. The sample was also racially/ethnically diverse, and the MIAS' acceptability and psychometric properties might vary by racial/ethnic subgroup. Finally, our results may not generalize to less diverse, higher SES populations.
Clinicians and researchers struggle with assessing medication adherence, perhaps because all methods have limitations (Gonzalez and Schneider, 2011) . Although technological advances may improve this (Driscoll & Young-Hyman, 2014) , a single method is unlikely to overcome measurement error, and self-report will remain the most feasible option in most settings. It is particularly well-suited for insulin self-administration where objective monitoring is difficult and cannot easily account for sliding-scale regimens. Self-reported adherence can also be as valid and can predict outcomes such as glycemic control as well as objective adherence measures . Thus, reservations about the accuracy of self-report should not deter the use of self-reported adherence in clinical and research settings. Our results highlight benefits to assessing insulin adherence while providing a tool for future research on insulin adherence.
